Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Recent studies have reported a higher risk of bleeding among patients that are co-administrated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) and anticoagulant, which raises our concern about the possible TKIs-warfarin pharmacokinetic and pharmacodynamic interaction that could be life-threatening to tumor patients who take warfarin for preventing deep vein thrombosis (DVT).
Methods: Influences of anlotinib and fruquintinib on the pharmacokinetic and dynamic behavior of warfarin were estimated. Influence on the activity of cytochrome P450 (CYP450) enzymes was detected in vitro through rat liver microsomes. Quantitative analysis of blood concentration in rats was finished by a validated UHPLC-MS/MS method. Furthermore, pharmacodynamic interactions were studied in rats by monitoring prothrombin time (PT) and activated partial thromboplastin time (APTT), while Inferior vena cava (IVC) stenosis-induced DVT model was built to further investigate the antithrombotic effect after co-administration.
Results: Anlotinib inhibited the activity of cyp2c6, cyp3a1/2 and cyp1a2 in rat liver microsomes in a dose-dependent manner, meanwhile enhanced the AUC and AUC of R-warfarin. However, fruquintinib showed no effects on pharmacokinetics of warfarin. Anlotinib and fruquintinib co-administrated with warfarin was found to exert more significant increase on PT and APTT values than that taking warfarin alone. In IVC stenosis-induced DVT model rats, the co-administration groups significantly reduced the length of thrombus compared with the single warfarin group.
Conclusions: Anlotinib and fruquintinib enhanced the anticoagulated and antithrombotic effect of warfarin. The anlotinib-induced interaction may due to the inhibition of the metabolism of warfarin. The mechanism of the pharmacodynamic interaction between fruquintinib and warfarin should be further investigated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejps.2023.106507 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anlotinib and fruquintinib co-administrated with warfarin increases the risk of bleeding: Studied from pharmacokinetic and pharmacodynamic perspectives.
Eur J Pharm Sci
September 2023
Department of Clinical Pharmacy, School of Pharmacy, Fudan University, 3728 Jinke Road, Pudong, Shanghai 201203, China. Electronic address:
Article Synopsis
- - Recent studies highlight a concerning risk of bleeding when combining vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) like anlotinib and fruquintinib with the anticoagulant warfarin, particularly affecting patients at risk for deep vein thrombosis (DVT).
- - Research investigated how anlotinib and fruquintinib influence warfarin's pharmacokinetics and pharmacodynamics using rat models, revealing anlotinib significantly inhibits enzymes that metabolize warfarin, increasing its blood concentration and enhancing its anticoagulant effects.
- - The findings suggest that while anlotinib increases the efficacy of warfarin, leading to better outcomes
Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib.
Neoplasma
November 2020
Dalian Medical University, Dalian, China.
The clinical efficiency and adverse reactions of anlotinib in metastatic colorectal cancer (mCRC) as a third-line treatment compared with chemotherapy and regorafenib or fruquintinib was explored in this study. Clinical data from 105 mCRC patients who failed at least two lines of chemotherapy were collected. The patients were divided into three groups based on their third-line therapeutic regimen: third-line chemotherapy only (group A); anlotinib (group B); and fruquintinib or regorafenib (group C).
View Article and Find Full Text PDFNew advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
J Cancer Res Clin Oncol
March 2020
Department of Respiratory Medicine, Shanghai Chest Hospital, Jiaotong University, Huaihai West Road No. 241, Shanghai, 200030, People's Republic of China.
Purpose: Tumor growth relies on the sufficient blood supply and continuously requires new blood vessels to maintain, which lead to vascular abnormalities (Folkman, N Engl J Med 285:1182-1186, 1971). Antiangiogenic therapy has emerged with the goal of normalizing vasculature and tumor microenvironment (TME). Some antiangiogenic therapies combined with chemotherapy, targeted therapy or immunotherapy have been approved for clinical application.
View Article and Find Full Text PDFMulti-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis.
Ann Transl Med
September 2019
Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
Background: Four multi-targeted tyrosine kinase inhibitors (TKIs) including apatinib, anlotinib, fruquintinib and lenvatinib are currently available as third-line regimen for advanced non-small cell lung cancer (NSCLC) patients who failed at least two lines of systemic therapy. Limited evidence was provided to demonstrate the general efficacy and safety profile of these drugs as third-line treatment approach for NSCLC.
Methods: Eligible literature was searched from electronic database.
Rapid advances in research on and development of anticancer drugs in China.
Biosci Trends
November 2019
Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
Article Synopsis
- Cancer poses a significant public health challenge in China, creating a strong demand for effective anticancer medications.
- The country has seen advancements in innovative drug development due to policy reforms and economic growth, leading to the approval of five new anticancer drugs by 2018.
- Future trends suggest a shift in China's pharmaceutical focus from generic medications to pioneering "first-in-class" and "best-in-class" drugs, with several more innovative treatments expected to gain approval soon.